Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by Chemoradiotherapy

• Yosuke Tanaka ,

  Contributed equally to this work with: Yosuke Tanaka, Kazuhiko Aoyagi, Keiko Minashi

  Affiliation Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan

  ⨯
• Kazuhiko Aoyagi ,

  Contributed equally to this work with: Yosuke Tanaka, Kazuhiko Aoyagi, Keiko Minashi

  Affiliation Department of Translational Oncology, National Cancer Center Research Institute, Tokyo, Japan

  ⨯
• Keiko Minashi ,

  Contributed equally to this work with: Yosuke Tanaka, Kazuhiko Aoyagi, Keiko Minashi

  Affiliation Department of Clinical Trial Promotion, Chiba Cancer Center, Chiba, Japan

  ⨯
• Rie Komatsuzaki,

  Affiliation Department of Translational Oncology, National Cancer Center Research Institute, Tokyo, Japan

  ⨯
• Masayuki Komatsu,

  Affiliation Department of Translational Oncology, National Cancer Center Research Institute, Tokyo, Japan

  ⨯
• Fumiko Chiwaki,

  Affiliation Department of Translational Oncology, National Cancer Center Research Institute, Tokyo, Japan

  ⨯
• Masashi Tamaoki,

  Affiliation Department of Translational Oncology, National Cancer Center Research Institute, Tokyo, Japan

  ⨯
• Takao Nishimura,

  Affiliation Department of Translational Oncology, National Cancer Center Research Institute, Tokyo, Japan

  ⨯
• Naoki Takahashi,

  Affiliation Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan

  ⨯
• Ichiro Oda,

  Affiliation Department of Gastrointestinal Oncology and Endoscopy, National Cancer Center Hospital, Tokyo, Japan

  ⨯
• Yuji Tachimori,

  Affiliation Department of Esophageal Surgery, National Cancer Center Hospital, Tokyo, Japan

  ⨯
• Tokuzo Arao,

  Affiliation Department of Genome Biology, Kinki University Faculty of Medicine, Osaka, Japan

  ⨯
• Kazuto Nishio,

  Affiliation Department of Genome Biology, Kinki University Faculty of Medicine, Osaka, Japan

  ⨯
• Shigehisa Kitano,

  Affiliation Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan

  ⨯
• Kenta Narumi,

  Affiliation Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan

  ⨯
• Kazunori Aoki,

  Affiliation Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan

  ⨯
• Satoshi Fujii,

  Affiliation Fundamental Innovative Oncology Core Center, National Cancer Center Research Institute, Tokyo, Japan

  ⨯
• Atsushi Ochiai,

  Affiliation Fundamental Innovative Oncology Core Center, National Cancer Center Research Institute, Tokyo, Japan

  ⨯
• Teruhiko Yoshida,

  Affiliation Division of Genetics, National Cancer Center Research Institute, Tokyo, Japan

  ⨯
• Manabu Muto ,

  * E-mail: yamada0304@aol.com (YY); mmuto@kuhp.kyoto-u.ac.jp (MM); hksasaki@ncc.go.jp (HS)

  Affiliation Department of Therapeutic Oncology, Kyoto University, Kyoto, Japan

  ⨯
• Yasuhide Yamada ,

  * E-mail: yamada0304@aol.com (YY); mmuto@kuhp.kyoto-u.ac.jp (MM); hksasaki@ncc.go.jp (HS)

  Affiliation Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan

  ⨯
•  [ ... ],
• Hiroki Sasaki

  * E-mail: yamada0304@aol.com (YY); mmuto@kuhp.kyoto-u.ac.jp (MM); hksasaki@ncc.go.jp (HS)

  Affiliation Department of Translational Oncology, National Cancer Center Research Institute, Tokyo, Japan

  ⨯
• [ view all ]
• [ view less ]